RICH.BA Laboratorios Richmond SACIF

Healthcare Pharmaceuticals Buenos Aires Exchange
1,300 ARS
Close of Oct 29, 2026
1,300 2,180
Market cap
ARS 105B
P/E
6.1x
P/B
0.76x
ROE
21.2%
Dividend yield
2.51%
Fundamental score
1.8/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is RICH.BA undervalued?

Graham number
Price1,300
Graham value2,869
Discount54.7%

RICH.BA trades 54.7% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Laboratorios Richmond SACIF fundamental analysis

8 of 22 checks passed

ROE 2/2

High return on equity (21.2%), above 20%.

ROA 0/1

Return on assets (5.6%) is below the industry median (5.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-90.2%) is not above the 5-year average (44.7% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-90.2%) is below the industry median (-3.6%).

Revenue Growth 2/2

Revenue grew 90.0% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (147.7%), above 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 0/1

EBIT is 2.5x against interest expense, below 5x.

PE vs Market 0/1

PE (7.4x) is above the market median (6.7x).

PE vs Industry 0/1

PE (7.4x) is above the industry median (5.8x).

PBV 0/1

Price to book (0.9x) is above the industry median (0.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 6.8, limit 22.5).

PEG 1/1

PEG on 5-year earnings growth is 0.17, growth is cheap.

Dividend Yield 1/2

Dividend yield (2.5%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 85.2%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Laboratorios Richmond SACIF stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Laboratorios Richmond SACIF

Laboratorios Richmond S.A.C.I.F., together with its subsidiaries, develops, manufactures, and sells pharmaceutical products in Latin America, Africa, Asia, and the Middle East. It offers antiretroviral drugs for the treatment of human immunodeficiency virus; oncology and oncohematology drugs; cardiometabolism drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs, such as analgesics, ant…

Full company profile